VanEck Australian Floating Rate ETF vs Nuwellis Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.97, while Nuwellis Inc trades at $2.9 (market cap $1.10M). The key difference: VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| FLOT | NUWE | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $51.09 | $558.26 |
52-Week Low | $50.72 | $2.80 |
Market Cap | — | $1.10M |
Enterprise Value | — | -$709.83K |
Signals from Pluang's Aura AI — not financial advice
FLOT (iShares Floating Rate Bond ETF) trades at $50.97, showing minimal daily movement with a neutral technical signal. The ETF focuses on high-quality floating rate bonds with a 4.0% SEC yield, positioning it as a defensive holding amid rising rate expectations. Recent dividends of $0.17-$0.18 reflect steady income generation, while technical indicators show mixed signals with bullish moving averages but bearish ADX readings.
The outlook remains stable with potential upside if the Federal Reserve implements rate hikes later in 2026, which would boost FLOT's yield. However, the ETF faces headwinds from inflation pressures and geopolitical tensions affecting Treasury yields. Current neutral sentiment suggests FLOT serves as a cash parking vehicle rather than a growth investment, with limited price appreciation potential but reliable income generation.
Nuwellis (NUWE) trades at $2.85, down 11.49% in the last session, reflecting ongoing financial challenges despite recent strategic initiatives. The stock shows a bearish technical outlook with negative cash flow and widening losses, though it maintains a high gross margin of 65.47%. Recent corporate actions include a 35:1 reverse stock split in June 2026 and a $6 million public offering to fund operations.
The outlook remains challenging with significant losses and negative profitability metrics, though new CEO leadership and patent developments offer potential catalysts. Investment opportunities exist in the company's niche pediatric cardiorenal market, while risks include cash burn, execution challenges, and competitive pressures in medical technology.
Trailing returns across standard periods
Latest headlines on both assets
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →